Johnson & Johnson Vision, the eye health division of Johnson & Johnson, has announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for ACUVUE® Theravision™ with Ketotifen -- a first-of-its-kind vision correction contact lens that doubles as an allergic eye itch solution.
The innovative new lens contains ketotifen, an H1 histamine receptor used to prevent eye itch associated with allergies. Of course, this solution is targeted specifically to contact lens wearers, who report higher rates of allergy-associated eye irritation. In addition, itchy allergy eyes are more likely to negatively impact contact lens wearers' vision, which results in many opting to switch to glasses during peak allergy season.
"We're proud to bring forward a new contact lens that simultaneously provides vision correction and relief of allergic eye itch, without the need for allergy eye drops," said Dr. Brian Pall, OD, MS, FAAO, Director, Clinical Science, Johnson & Johnson Vision Care.
Anti-Allergy Contact Lenses
ACUVUE Theravision Contacts are Designed to Comfort Allergic Eye Itch
Trend Themes
1. Anti-allergy Contact Lenses - Johnson & Johnson's new Theravision contact lenses containing ketotifen offer a new solution for allergy-associated eye irritations.
2. Dual Purpose Contact Lenses - Developers can design contact lenses to serve multiple purposes beyond simple vision correction.
3. Medical Technology in Contact Lenses - Medical technology like ketotifen can be incorporated to provide advanced medical solutions without the need for injections or oral medications.
Industry Implications
1. Optometry - Optometrists and eye care specialists can leverage this trend to improve the effectiveness of their products and the satisfaction of their patients.
2. Pharmaceuticals - Pharmaceutical companies can explore the potential of incorporating medicines into contact lenses to combat various medical issues.
3. Medical Devices - Contact lens manufacturers can include medical technologies that make their products more appealing to users.